Group 1 - GE HealthCare Technologies reported revenue of $5.01 billion for the quarter ended June 2025, representing a 3.5% increase year-over-year and a surprise of +0.66% over the Zacks Consensus Estimate of $4.97 billion [1] - The earnings per share (EPS) for the quarter was $1.06, compared to $1.00 in the same quarter last year, resulting in an EPS surprise of +16.48% against the consensus estimate of $0.91 [1] - Over the past month, GE HealthCare shares returned +2.3%, while the Zacks S&P 500 composite increased by +3.4%, with the stock currently holding a Zacks Rank 3 (Hold) [3] Group 2 - Revenue from Imaging was $2.2 billion, slightly below the average estimate of $2.21 billion, reflecting a year-over-year decrease of -15.1% [4] - Advanced Visualization Solutions (AVS) generated $1.29 billion, exceeding the estimated $1.27 billion, with a significant year-over-year increase of +56.6% [4] - Revenue from Pharmaceutical Diagnostics (PDx) was $729 million, surpassing the estimated $699.23 million, marking a year-over-year increase of +14.1% [4] - Patient Care Solutions (PCS) reported revenue of $778 million, slightly below the average estimate of $784.09 million, with a year-over-year change of +0.8% [4] - Other revenues were reported at $6 million, significantly lower than the estimated $10.29 million, representing a year-over-year decline of -33.3% [4]

Core Insights - GE HealthCare Technologies (GEHC) reported revenue of $4.78 billion for the quarter ended March 2025, reflecting a year-over-year increase of 2.7% and exceeding the Zacks Consensus Estimate of $4.66 billion by 2.57% [1] - The company's earnings per share (EPS) was $1.01, up from $0.90 in the same quarter last year, resulting in an EPS surprise of 10.99% compared to the consensus estimate of $0.91 [1] Revenue Breakdown - Imaging revenues were reported at $2.14 billion, surpassing the average analyst estimate of $2.03 billion, but showing a decline of 13.2% year-over-year [4] - Other revenues amounted to $13 million, slightly below the estimated $13.30 million, with a year-over-year decrease of 13.3% [4] - PDx revenues reached $632 million, slightly above the estimate of $631.52 million, marking a year-over-year increase of 5.5% [4] - PCS revenues were reported at $753 million, exceeding the average estimate of $749.38 million, with a year-over-year growth of 0.8% [4] Stock Performance - Over the past month, GE HealthCare shares have returned -14.4%, contrasting with a -0.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]